- Home
- RRX vs ROIV Comparison
RRX vs ROIV Comparison
Compare RRX & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RRX
- ROIV
- Stock Information
- Founded
- RRX 1955
- ROIV 2014
- Country
- RRX United States
- ROIV United Kingdom
- Employees
- RRX N/A
- ROIV N/A
- Industry
- RRX
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- RRX
- ROIV Health Care
- Exchange
- RRX Nasdaq
- ROIV Nasdaq
- Market Cap
- RRX 10.4B
- ROIV 8.6B
- IPO Year
- RRX 1987
- ROIV N/A
- Fundamental
- Price
- RRX $140.31
- ROIV $15.28
- Analyst Decision
- RRX Strong Buy
- ROIV Strong Buy
- Analyst Count
- RRX 10
- ROIV 4
- Target Price
- RRX $177.80
- ROIV $15.50
- AVG Volume (30 Days)
- RRX 690.8K
- ROIV 7.8M
- Earning Date
- RRX 11-03-2025
- ROIV 11-11-2025
- Dividend Yield
- RRX 1.00%
- ROIV N/A
- EPS Growth
- RRX N/A
- ROIV N/A
- EPS
- RRX 3.76
- ROIV N/A
- Revenue
- RRX $5,852,700,000.00
- ROIV $23,233,000.00
- Revenue This Year
- RRX N/A
- ROIV N/A
- Revenue Next Year
- RRX $3.91
- ROIV $281.14
- P/E Ratio
- RRX $37.37
- ROIV N/A
- Revenue Growth
- RRX N/A
- ROIV N/A
- 52 Week Low
- RRX $90.56
- ROIV $8.73
- 52 Week High
- RRX $185.28
- ROIV $16.05
- Technical
- Relative Strength Index (RSI)
- RRX 43.03
- ROIV 82.00
- Support Level
- RRX $137.79
- ROIV $13.81
- Resistance Level
- RRX $146.02
- ROIV $14.48
- Average True Range (ATR)
- RRX 4.63
- ROIV 0.47
- MACD
- RRX -0.68
- ROIV 0.22
- Stochastic Oscillator
- RRX 15.17
- ROIV 81.67
About RRX Regal Rexnord Corporation
Regal Rexnord Corp is in the engineering and manufacturing of industrial powertrain solutions, power transmission components, electric motors, electronic controls, air-moving products, and specialty electrical components and systems, serving customers around the world. The four operating segments include Commercial Systems, Industrial Systems, Climate Solutions, and Motion Control Solutions.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.